ELV VS AMGN Stock Comparison

Performance

ELV
100/100

ELV returned -5.17% in the last 12 months. Based on SPY's performance of -12.93%, its performance is above average giving it a score of 100 of 100.

AMGN
10/100

AMGN returned -3.87% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

ELV
61/100

ELV receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.

AMGN
93/100

AMGN receives a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.

Earnings

ELV
100/100

ELV has missed earnings 0 times in the last 20 quarters.

AMGN
100/100

AMGN has missed earnings 1 times in the last 20 quarters.

Profit

ELV
70/100

Out of the last 20 quarters, ELV has had 20 profitable quarters and has increased their profits year over year on 8 of them.

AMGN
63/100

Out of the last 20 quarters, AMGN has had 19 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

ELV
42/100

ELV has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

AMGN
44/100

AMGN has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

ELV

"Analyst Price Targets" not found for ELV

AMGN
63/100

25 analysts offer 12-month price targets for AMGN. Together, they have an average target of 0, the most optimistic target put AMGN at 0 within 12-months and the most pessimistic has AMGN at 0.

Dividend

ELV

"Dividend" not found for ELV

AMGN
87/100

AMGN's most recent dividend was $1.32 per share, based on a share price of $273.03. It was a payout ratio of 43.57% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Elevance Health, Inc. Summary

New York Stock Exchange / ELV

Healthcare

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Amgen Inc Summary

Nasdaq / AMGN

Healthcare

Drug Manufacturers - General

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Power up your portfolio